Global Drugs for Vulvovaginal Candidiasis Market Growth 2023-2029

Global Drugs for Vulvovaginal Candidiasis Market Growth 2023-2029

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
LPI (LP Information)' newest research report, the “Drugs for Vulvovaginal Candidiasis Industry Forecast” looks at past sales and reviews total world Drugs for Vulvovaginal Candidiasis sales in 2022, providing a comprehensive analysis by region and market sector of projected Drugs for Vulvovaginal Candidiasis sales for 2023 through 2029. With Drugs for Vulvovaginal Candidiasis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs for Vulvovaginal Candidiasis industry.
This Insight Report provides a comprehensive analysis of the global Drugs for Vulvovaginal Candidiasis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for Vulvovaginal Candidiasis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Drugs for Vulvovaginal Candidiasis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for Vulvovaginal Candidiasis and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for Vulvovaginal Candidiasis.
The global Drugs for Vulvovaginal Candidiasis market size is projected to grow from US$ 798.8 million in 2022 to US$ 890 million in 2029; it is expected to grow at a CAGR of 890 from 2023 to 2029.
The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.
The Asia-Pacific region is the world's largest market, with a market share of about 45%, followed by North America with nearly 20%
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Vulvovaginal Candidiasis market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Cream
Pessary
Other
Segmentation by application
Hospital & Clinic
Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Key Questions Addressed in this Report
What is the 10-year outlook for the global Drugs for Vulvovaginal Candidiasis market?
What factors are driving Drugs for Vulvovaginal Candidiasis market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Drugs for Vulvovaginal Candidiasis market opportunities vary by end market size?
How does Drugs for Vulvovaginal Candidiasis break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.